Vaccines against SARS‐CoV‐2 are safe to administer in patients with antibodies to pegaspargase

OBJECTIVE: Allergic reactions to pegaspargase during ALL therapy are typically due to antibodies against polyethylene glycol (PEG), which is also used as a stabilizing agent in mRNA‐based SARS‐CoV‐2 vaccines. To evaluate the safety of these vaccines in patients with anti‐pegaspargase antibodies. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Swanson, Hope D., Hakim, Hana, Hijano, Diego R., Morton, Ted, Cross, Shane, Inaba, Hiroto, Jeha, Sima, Pui, Ching‐Hon, Karol, Seth E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349948/
https://www.ncbi.nlm.nih.gov/pubmed/35837830
http://dx.doi.org/10.1002/cam4.5011